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Poster Session II S287patients, donor hematopoiesis is accounted for by one unit, although
the mechanisms of unit dominance are not established. Cord blood
NK cells are predominantly of a mature phenotype, with cytotoxic
activity following IL-2 stimulation comparable to peripheral blood
NK cells, but with higher proliferation capacity. We, therefore, hy-
pothesized that NK cells may determine unit dominance following
DCBT. We examined KIR haplotypes of each unit, and the unit-
unit and unit-recipient KIR-HLA interactions in 83 DCBT recipi-
ents transplanted at MSKCC between October 2005 and July 2010
for hematological malignancies. Median age of patients was 35.6
years (0.9-64.6). Patients received myeloablative (n 5 65) or non-
myeloablative (n 5 18) conditioning, and immunosuppression with
a calcineurin inhibitor and mycophenolate mofetil. Chi-square test
was used to examine the frequency distributions differences of spe-
cific KIR haplotypes and individual activating KIR between the pre-
dominating and the non-engrafting units. It was also used to test
equal frequency distributions of inhibitory KIR-mediatedmissing li-
gand ormissing self. Group B-haplotypes (34.9% vs. 41.4%, p5 0.2)
were not associated with a higher likelihood of unit dominance. Sim-
ilarly, none of the individual activating KIR showed any association
with unit dominance. The majority of unit pairs either had no KIR-
HLA combinations predictive of NK alloreactivity (n 5 20), or had
NK alloreactivity predicted to occur in a bidirectional manner (n 5
35). Results from unit-unit interaction analyses showed that units
missing KIR ligand (16/29 vs 13/29, p5 0.71), or lacking class I de-
terminants present in the second unit (12/18 vs 6/18, p 5 0.23), did
not show a lower rate of engraftment. For unit-recipient interac-
tions, cord blood units did not have a higher likelihood of engraft-
ment even if the patient was missing ligand for the unit inhibitory
KIR (2/7 vs. 5/7, p 5 0.45), or lacked class I determinants present
in the unit (7/16 vs. 9/16 p 5 0.80). Results from recipient-unit in-
teraction analyses revealed that units missing KIR ligand (12/25 vs.
13/25, p5 1.00) or lacking class I determinants present in the recip-
ient (9/19 vs. 10/19, p 5 1.00) did not show a lower rate of engraft-
ment. In this cohort of DUCBT, we could not demonstrate a role for
KIR-HLA genotypes or KIR haplotypes in predicting cord unit
predominance.368
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Allogeneic hematopoietic stem cell transplantation(HSCT) must
serve as a platform for adoptive cellular immunotherapy to fully ex-
ploit graft versus leukemia effects. We have developed a 4-log ex-
vivo T lymphocyte depleted HSCT with minimal graft versus host
disease (GvHD) prophylaxis followed by elective donor lymphocyte
infusion at day 90. A lymphodepleted environmentwithout immuno-
suppressionwould favor homeostatic expansion of adoptively infused
cells in future protocols. 39 patients with hematologic malignancies
underwent allogeneic HSCT with a graft from their HLA-identical
siblings. The median age was 41 years (range 16-68), 17/39 were
males. Transplant indications were AML(18), ALL(8), acute biphe-
notypic leukemia(1), MDS(7), NHL/CLL(3), CMMoL(1) and
CML(1). 50% were standard risk and 50% were at high risk for re-
lapse. Subjects received myeloablative conditioning with cyclophos-
phamide (60 mg/kg/dose x 2), fludarabine (25 mg/m2/dose x 5) and
total body irradiation (12 Gy in 8 fractions, lungs shielded to 6Gy).
Ten subjects,whowere 55 years of age or older, received 4Gydivided
in 8 fractions without lung shielding. G-CSF mobilized peripheral
blood grafts from the donor were CD34+ selected (Miltenyi Clini-
Macs), with infusion of a target CD34+ dose of 6x10e6/kg and a fixed
CD3+ dose of 5x10e4/kg. Low-dose cyclosporine (100-200ng/mL)
till day 21 was the only GVHD prophylaxis. Delayed lymphocyte
add back (5x10e6CD3+/kg) was given at day 90 if patients had no sig-
nificant GVHD. CD3+ and myeloid chimerism analyses were per-
formed with early lymphocyte add-back in cases with fallingchimerism. Day 200 overall survival (the primary study endpoint)
was 84%. One patient, who was postpartum, failed to engraft and re-
quired a second transplant. 37/39 subjects achieved complete
(. 95%) donor myeloid chimerism by day14. The median times to
complete donor CD3+ chimerism were day30 for 12 Gy subjects
and . 6 months for 4 Gy subjects (Mann Whitney test, p 5 0.004).
The incidence of acute GVHD grade II, III and IV were 23%,
2.9% and 0%, respectively. The incidence of chronic GVHD was
34%. At a median follow up of 3.7 years, Kaplan-Meier estimates
of relapse, nonrelapse mortality and overall survival were 32%,
31% and 46% respectively without any significant difference based
on conditioning intensity. In conclusion, conditioning intensity in-
fluences the rapidity of complete donor CD3+ chimerism in trans-
plants utilizing this platform for adoptive cellular immunotherapy.369
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In leukemia patients, peripheral blood stem cells (PBSC) have re-
placed bone marrow (BM) as stem cell source. No study has shown
any benefit using PBSC versus BM in matched unrelated donor
(MUD) transplantation. We therefore compared PBSC and BM in
MUD recipients with acute myeloid leukemia (AML).
Between 1997 and 2008, 760 patients received BM and 1,502
PBSC from a MUD. The PBSC group were older age (p\ 0.01),
had more advanced disease (p\0.0001), received less total body ir-
radiation (p\0.0001), and more antithymocyte globulin (p5 0.01).
Recovery of neutrophils and platelets was faster with PBSC (p\
0.0001). Acute GVHD was similar, but chronic GVHD was in-
creased in the PBSC group (HR 1.29, p 5 0.02). Non-relapse mor-
tality (NRM), relapse and leukemia-free survival (LFS) did not differ
between the two groups, in AML patients in remission. However, in
patients with advanced AML, NRM was decreased (HR 0.61, p 5
0.02) and LFS was improved (HR 1.49, p 5 0.002) using PBSC.
At 3 years, LFS for all patients, regardless of remission status, was
4161% for both groups.
PBSC compared to BM in MUD transplants in AML resulted in:
faster neutrophil and platelet recovery, not statistically different
acute GVHD, increased chronic GVHD and same rates of LFS in
remission patients. In advanced AML, the PBSC group had
decreased NRM and improved LFS.370
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Achieving engraftment of T cell depleted BMT under reduced in-
tensity conditioning (RIC) remains a major challenge. Recently, we
demonstrated that anti 3rd-party CD8 T cells with ex-vivo induced
central memory phenotype (Tcm) can enhance BM engraftment
S288 Poster Session IIwith markedly reduced risk for GVHD in lethally irradiated mice
(Ophir et al Blood 2010). We now show that these Tcm can also en-
hance engraftment following sublethal TBI (5.5Gy). Thus, while all
13 BALB/c recipients of 107 Nude-B6 BM cells rejected the graft by
day 30, 6/7mice receiving also 5x106 (B6xBALB/c)F1Tcm exhibited
near full chimerism (81611%,. 6 months follow up). Importantly,
chimerism was associated with successful engraftment of donor skin
(. 3 months follow up) in 4/5 chimeras, while 3rd-party unrelated
skin was promptly rejected. When allogeneic B6 Tcm were used,
9/9 mice displayed full donor chimerism and 5/7 maintained donor
skin for over 3 months, without any GVHD symptoms (weight and
overall appearance were the same as that of control mice). Consider-
ing that RIC may be associated with increased relapse rate, it was of
interest to evaluate the GVL reactivity of Tcm. We previously
showed that anti 3rd-party human CTLs eliminate B-CLL and other
lymphoma types by unique TCR independent mechanism. This kill-
ing initiates with ICAM1-LFA1 adhesion, followed by slow apopto-
sis induced by interaction of CD8 on the CTL with MHC-I on the
tumor cell. Initially, we verified that the anti 3rd-party Tcm can also
kill murine A20 lymphoma cells in-vitro (34.8612.1% after 16hrs of
co-incubation). This killing was mediated by apoptosis (AnnexinV
staining of A20 cells increased from 5.262%, to 14.864.5%, p\
0.05). Next, using a model simulating minimal residual disease, we
followed luciferase expressing A20 cells in-vivo, and studied the ef-
fect of adding Tcm to BMT. Thus, lethally irradiated BALB/c
mice were transplanted with 3x106 allogeneic Nude B6 BM and
5000 A20 cells.While all 8 untreated mice died from tumor overload
by day 28, treatment with 5x106 donor type Tcms one day post BMT
led to tumor elimination and overall survival of 100% (7/7) 100 days
post BMT, without any manifestation of GVHD.
Collectively, our data suggest that anti 3rd-party Tcm can provide
a ‘double supportive effect’ by promoting BM engraftment under
RIC, and inducing GVL reactivity, without causing GVHD. Such
cell therapy could be highly attractive for patients with B cell malig-
nancies who might not tolerate aggressive conditioning.371
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This study compared the results of allogeneic peripheral blood
stem cell transplantation (PBSCT) from unrelated and related do-
nors in 142 consecutive patients with AML. Among these patients,
101 (71.1%) received an HLA-matched related PBSCT and 41
(28.9%) an HLA-matched unrelated PBSCT. High-risk AML was
defined as the presence of adverse cytogenetics or failure to achieve
CR. Among the 41 (28.9%) patients assigned to the high-risk group,
35 (85.4%) patients had failed to achieve CR and 7 patients (17.1%)
had adverse cytogenetics. The cumulative incidence of acute graft-
versus-host disease (GVHD)was 37.6% in the related PBSCTgroup
and 53.7% in the unrelated PBSCT group. The cumulative inci-
dence of extensive chronic GVHD was higher in the unrelated
PBSCT group (19.5%) than in the related PBSCT group (8.9%).
The overall survival (OS) rate at 4 years was 62.465.4% and
53.861.2% and the cumulative incidence of relapse was 24.8%
and 12.2% in the related and unrelated PBSCT groups, respectively.
In a multivariate analysis, unrelated PBSCT was identified as a risk
factor for the development of extensive chronicGVHD (hazard ratio
5 3.019, P-value5 0.027). Among the factors examined, unfavorable
cytogenetics and the disease status at the time of transplantationwere
found to be related with overall survival. In the case of high-risk
AML, the survival rate and relapse incidencewere significantly better
in thematched unrelated PBSCTgroup (P-value5 0.047, P-value5
0.039, respectively). In conclusion, the alloPBSCT outcomes for
AML were comparable in the matched related and matched unre-
lated groups. Nonetheless, for high-risk AML patients, matched un-
related PBSCT was found to be preferable to matched related
PBSCT.372
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Adoptive cell transfer of FoxP3+ regulatory T cells (Tregs) has
been proposed as a novel therapy for prevention of acute GVHD.
Such therapy may theoretically be limited by conversion of Tregs
into pathological effector T cells due to STAT3-activating inflam-
matory cytokines, including IL-6, IL-21, and IL-23. To better un-
derstand the role of STAT3 in Treg cell plasticity during acute
GVHD, we used a B6 0 BALB/c transplantation model. Donor
cell populations were obtained from either, STAT3 fl/fl Foxp3-
GFP (WT) or CD4-Cre, STAT3 fl/fl-Foxp3 GFP (KO). Transfer
of T cell-replete, WT inocula uniformly resulted in lethality by
day 14 post-BMT; in contrast, T cell-replete, STAT3-KO recipients
had 100% post-BMT survival (p\ 0.001). Relative to WT recipi-
ents, STAT3-KO recipients also had less GVHD by histology as-
sessment (p\ 0.05) and had increased numbers of splenic FoxP3+
T cells post-BMT (p 5 0.005); in contrast, WT recipients had in-
creased IL-17 and IFN-g secreting T cells post-BMT (each, p\
0.01). The increased number of post-BMT FoxP3+ cells in
STAT3-KO recipients may have been due to: (1) increase in ‘‘in-
duced’’ Tregs from the na€ıve T cell pool; and (2) decrease in loss
of ‘‘natural’’ (n)Tregs. Purified, na€ıve, FoxP3 negative T cells from
WT or STAT3KO donors were transferred to evaluate the first pos-
sibility: after allogeneic BMT, FoxP3 induction was greatly in-
creased in STAT3-KO recipients relative to WT recipients (p \
0.01). And, to address the second possibility, purified WT and
STAT3-KO FoxP3+ Tregs were co-infused with conventional do-
nor T cells: relative to recipients of WT nTregs, recipients of
STAT3-KO nTregs had greatly increased post-BMT numbers of
FoxP3 post-BMT (p\0.05). As such, the in vivo pool of Treg cells
after allogeneic BMT is controlled to a great extent by STAT3 sig-
naling, which influences both natural and induced Treg pathways.373
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Purpose: We retrospectively assessed changes in the incidence and
causes of non-relapse mortality (NRM) over the last 12 years in
allo-HCT patients.
Methods:We analyzed a nationwide registry database that includes
patients aged 16 years or older with AML or ALL in remission, or
low-risk MDS who received allo-HCT from 1997 to 2008. We
compared the incidence of NRM and overall survival (OS) after
allo-HCT in three consecutive four-year periods (1997-2000,
2001-2004, and 2005-2008) for younger patients (16-49 years), and
in the later two periods for older patients ($ 50 years). Subgroup
analyses were performed based on patient age and donor source:
HLA-matched/1-Ag mismatched related donor (related donor)
versus unrelated BM or CB donor (alternative donor).
Results: A total of 6517 patients with a median age of 40 years were
analyzed and the median follow-up was 39 months. A total of 1354,
2298, and 2865 allo-HCT were performed in 1997-2000, 2001-
2004, and 2005-2008, respectively. The incidence of NRM was
23% at 3 years after allo-HCT. A subgroup analysis of younger pa-
tients who received allo-HCT from a related donor showed that
there was no significant change in NRM (12-15%). In younger pa-
tients who received allo-HCT from an alternative donor, the
